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11b-Hydroxysteroid dehydrogenase in human vascular cells. zyme (11bHSD1) catalyzes both 11b-dehydrogenation
Aldosterone selectivity in mineralocorticoid target tissues is and the reverse oxoreduction and is a low-affinity nico-
mainly due to 11b-hydroxysteroid dehydrogenase (11bHSD), tinamide adenine dinucleotide phosphate enzyme [4].which converts cortisol to its inactive metabolite cortisone in
Recently, it has been suggested that 11bHSD1 functionshumans. The defect of dehydrogenase activity would thus allow
as a predominant 11b-reductase, regenerating active glu-type 1 mineralocorticoid receptor (MR) to be occupied mostly
by cortisol. It has been postulated that 11bHSD type 2 cocorticoids from circulating inactive 11-keto forms and
(11bHSD2) plays a significant role in conferring ligand speci- modulates glucocorticoids access to glucocorticoid re-
ficity on the MR. We have demonstrated the diminished dehy- ceptors (GRs) [5]. The enzyme has been detected in adrogenase activity in resistance vessels of genetically hyperten-
wide range of rat and human tissues, including liver,sive rats. However, the mechanism that could link impaired
lung, and testis. A second isozyme (11bHSD2) is presentvascular 11bHSD activity and elevated blood pressure has been
unclear. In this study, we showed the enzyme activity in human in the kidney and placenta. It is a high-affinity nicotin-
coronary artery smooth muscle cells. Glucocorticoids and min- amide adenine dinucleotide (NAD)-dependent enzyme
eralocorticoids increase vascular tone by up-regulating the re-
and catalyzes only 11b-dehydrogenation [6]. It has beenceptors of pressor hormones such as angiotensin II (Ang II).
believed that in congenital 11bHSD deficiency (apparentNext, we found that physiological concentrations of a cortisol-
induced increase in Ang II binding were significantly enhanced mineralocorticoid excess syndrome) and after the admin-
by the inhibition of dehydrogenase activity with an antisense istration of 11bHSD inhibitors (licorice and carbenoxo-
DNA complementary to 11bHSD2 mRNA, and the enhance- lone), suppression of the dehydrogenase activity in the
ment was partially but significantly abolished by a selective
kidney has been believed to cause renal mineralocorti-aldosterone receptor antagonist. This may indicate that im-
coid excess, resulting in sodium retention and hyperten-paired dehydrogenase activity in vascular wall results in in-
creased vascular tone by the contribution of cortisol, which sion [7, 8]. However, we have demonstrated diminished
acts as a mineralocorticoid. In congenital 11bHSD deficiency dehydrogenase activity in resistance vessels of geneti-
and after the administration of 11bHSD inhibitors, suppression cally hypertensive rats [9]. Since local glucocorticoidsof dehydrogenase activity in the kidney has been believed
(mineralocorticoids as well) within vascular wall couldto cause renal mineralocorticoid excess, resulting in sodium
directly affect vascular tone by up-regulating the recep-retention and hypertension. These results show that vascular
11bHSD activity could influence blood pressure without invok- tors of pressor hormones such as angiotensin II (Ang
ing renal sodium retention. II) [10], the local metabolism of glucocorticoids mediated
by 11bHSD may be important in controlling blood pres-
sure. The present study aimed to clarify the physiological
Type 1 mineralocorticoid receptor (MR) has an equal and pathophysiological significance of 11bHSD activity
affinity for cortisol and aldosterone, despite the fact that in human resistance vessels. We investigated the enzyme
the circulating cortisol levels are much higher than those activity in human coronary artery smooth muscle cells
of aldosterone [1]. It has been proposed that the abun- (HCASMCs). Furthermore, to assess its potential role
dance of 11b-hydroxysteroid dehydrogenase (11bHSD) as a modulator of vascular tone, a functional relationship
in the kidney, which metabolizes cortisol into cortisone between the vascular 11bHSD activity and the effect
with a very low affinity for the MR, explains how the of physiological concentrations of cortisol on Ang II
kidney can be a mineralocorticoid target tissue [2, 3]. A receptor regulation was also tested by manipulating
defect of 11bHSD activity would thus allow the MR to 11bHSD2 gene expression with an antisense DNA.
be occupied mostly by cortisol. In humans, two 11bHSD
isozymes have been described and cloned. The first en-
METHODS
MaterialsKey words: 11bHSD2, angiotensin II receptor, cortisol, vascular tone,
hypertension, blood pressure. Human coronary artery smooth muscle cells (Clonetics
Corp.) were cultured according to the supplier’s instruc-Ó 2000 by the International Society of Nephrology
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tively [11]. 11bHSD activities were measured by a
radiometric conversion assay, as previously described
[12]. In brief, confluent HCASMCs were incubated in a
hydrocortisone-free and serum-free medium containing
100 nmol/L [1,2,6,7-3H]cortisol or [1,2,6,7-3H]cortisone
for eight hours, after which steroids were extracted with
chloroform and were resolved by thin-layer chromatog-
raphy (TLC). Radioactivities corresponding to cortisol
and cortisone were determined. Dehydrogenase and re-
ductase activities were calculated as cpm for cortisone/
(cpm for cortisol 1 cpm for cortisone) 100 and cpm
for cortisol/(cpm for cortisol 1 cpm for cortisone) 100,
respectively. [1,2,6,7-3H]cortisone was prepared from
[1,2,6,7-3H]cortisol, as described previously [13]. Briefly,
the labeled cortisol (10 mCi) was incubated in 1 mL
of 50% aqueous acetic acid containing 1% chromium
trioxide at room temperature for 20 minutes. The residue
from the dichloromethane extract of the reaction prod-
ucts was chromatographed by TLC with the use of chlo-
roform:methanol (9:1) as the solvent and nonradioactive
cortisol and cortisone as reference markers. The corti-
sone-containing region was scraped off and eluted with
ethyl acetate.
Fig. 1. 11b-Hydroxysteroid dehydrogenase (11bHSD) activity in hu-
Angiotensin II bindingman coronary artery smooth muscle cells (HCASMCs). Dehydrogenase
and oxoreductase activities were calculated as described in the Methods Confluent HCASMCs were washed three times with
section. Open columns represent data from experimental blanks. (Re-
saline and incubated with 1Sar, [125I] 4Tyr, 8Ile-Ang II forprinted with permission from Lippincott Williams & Wilkins, Hyperten-
sion [9].) 60 minutes at room temperature. Assay buffer consisted
of 50 mmol/L Tris (pH 7.4), 100 mmol/L NaCl, 5 mmol/L
MgCl2, 0.25% bovine serum albumin (BSA), and 0.5 mg/
mL bacitracin. At the end of incubation, the cells were
tion. 1Sar, [125I] 4Tyr, 8Ile-Ang II were purchased from washed with saline four times, solubilized in 1% sodium
NEN-DuPont (Bad Homburg, Germany). [1,2,6,7- dodecyl sulfate (SDS), and counted with a g-counter.
3H]cortisol was from Amersham International PLC (Ar- Scatchard analysis of the binding data revealed a single
lington Heights, IL, USA). Cortisol, cortisone, spirono- class of high-affinity (0.31 6 0.06 nmol/L) and low-capac-
lactone, and RU38486 were from Sigma (St. Louis, MO, ity (10.8 6 0.5 fmol/mg protein, 468 6 21 sites/cell) bind-
USA). Ang II was from the Peptide Institute (Osaka, ing sites. Competition binding study showed that radioli-
Japan). DuP753 and PD123319 were from Yamanouchi gand binding was potentially inhibited by unlabeled Ang
Pharmaceutical Co. (Tokyo, Japan). II and nonpeptide Ang II type 1 receptor antagonist
DuP 753; however, type 2 receptor antagonist PD123319Cell culture
had no effect on the binding of [125I]Ang II, indicating
Human coronary artery smooth muscle cells were cul- that HCASMCs exhibited high-affinity Ang II type 1
tured to confluence in Dulbecco’s modified Eagle’s me- receptor.
dium with 5% fetal calf serum (FCS) plus 4 mg/mL of
Antisense oligonucleotidesgentamicin under 5% CO2/95% air at 378C. Cells at 5
to 8 passages were used for the experiments; more than A 24-mer phosphorothioate antisense oligonucleotide
95% of the cells were identified as smooth muscle cells (AS) complement of the 59 region of human 11bHSD2
by their typical “hill-and-valley” morphology and by im- mRNA containing the initiator AUG codon and as a
munofluorescence with the use of a monoclonal antibody control, a nonsense oligonucleotide (NS) containing the
against human a-smooth muscle actin. same base composition but in a random, scrambled order
were synthesized with an Applied Biosystems Model
Assay of 11b-hydroxysteroid dehydrogenase activity 392 DNA synthesizer (PE Biosystems, Foster City, CA,
The apparent Km values for the dehydrogenase reac- USA) [14]. Sequences of AS and NS were 59-CGACGG
tion and the reductase reaction in vascular smooth mus- CCAAGGCCAGCGCTCCA-39 and 59-TCACGCACG
CGCCAACCGCGGAGT-39, respectively.cle cells are approximately 100 and 300 nmol/L, respec-
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Fig. 2. Effect of antisense oligonucleotides
on 11bHSD activities in HCASMCs. After
confluent cells had been incubated in the pres-
ence of antisense oligonucleotide (AS) or non-
sense oligonucleotide (NS) for 24 hours, dehy-
drogenase (h) and oxoreductase ( ) activities
were determined. *P , 0.01, compared with
cells cultured without oligonucleotides. (Re-
printed with permission from Lippincott Wil-
liams & Wilkins, Hypertension [9].)
Statistical analysis either activity. No visible signs of toxicity were observed.
Since the oxoreductase activity was unaffected, the pres-Data are expressed as the mean 6 SEM. The signifi-
ent results indicate that the inhibitory effect of AS iscance of differences was assessed by one-way analysis
due to a specific decrease of 11bHSD2 activity.of variance (ANOVA) and multiple comparison test
(N 5 6). Values of P , 0.05 were accepted as statistically
Effect of cortisol on angiotensin II bindingsignificant.
Next, we examined the effect of cortisol on Ang II
binding in these cells. Incubation of HCASMCs for 24
RESULTS hours with cortisol resulted in concentration-dependent
11b-Hydroxysteroid dehydrogenase activity in human increases in Ang II binding, with a maximal increase
coronary artery smooth muscle cells (98 6 10%) at 1 mmol/L cortisol (Fig. 3A). The competi-
tion binding data and the Scatchard analysis of the bind-To assess 11bHSD activities, labeled cortisol or its
ing data from control cells and cells treated for 24 hoursmetabolite cortisone was added to each medium. Incuba-
with cortisol demonstrated that Ang II receptors up-tion with cortisol resulted in moderate (18 6 2%) conver-
regulated by cortisol (as well as basal Ang II receptors)sion to cortisone after eight hours, whereas incubation
were of the type 1 receptor, and the affinity was notwith cortisone resulted in more conversion (42 6 5%)
significantly changed (data not shown). Up-regulationto cortisol (Fig. 1). Thus, HCASMCs were capable of
of Ang II binding was completely inhibited by RU38486,performing the dehydrogenase as well as the reverse
a specific antagonist for GRs, but not by spironolactone,oxoreductase phase of the reaction, and under physiolog-
a selective antagonist for MR, indicating that the regula-ical conditions, these cells favored the latter phase.
tion was mediated through GR (Fig. 3B). RU38486 or
Effect of 11b-hydroxysteroid dehydrogenase type 2 spironolactone alone did not alter Ang II binding (data
antisense oligonucleotides not shown).
As shown in Figure 2, incubation of HCASMCs for
Effect of 11b-hydroxysteroid dehydrogenase type 224 hours with the AS induced dose-dependent decreases
activity on angiotensin II bindingin the dehydrogenase activity of HCASMCs, with a maxi-
After confluent HCASMCs had been incubated withmal decrease (78 6 6%) at 10 mmol/L AS, but the oxore-
ductase activity was unaffected. The NS did not alter the oligonucleotides for 24 hours, the cells were further
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both spironolactone and RU38486 were dose dependent,
with a maximal inhibition (24 6 3%) at 1 mmol/L spiro-
nolactone (72 6 6% inhibition with 1 mmol/L RU38486).
Concomitant administration of both spironolactone and
RU38486 completely inhibited the up-regulation of Ang
II binding. Mineralocorticoids are known to increase the
Ang II receptor number through its action on MR [15].
Our results indicate that diminished vascular 11bHSD2
activity enhances the effect of cortisol, and the enhance-
ment is mediated through both GR activation by cortisol
as a glucocorticoid and MR activation by cortisol as
a mineralocorticoid, suggesting that 11bHSD2 plays a
significant role in conferring the ligand specificity on MR
in HCASMCs.
DISCUSSION
We demonstrated, to our knowledge for the first time,
the bidirectional activity of 11bHSD in vascular smooth
muscle cells. These cells favored the oxoreductase reac-
tion under physiological conditions. It has been sug-
gested that the 11bHSD1 may function as a predominant
11b-reductase, regenerating active cortisol from circulat-
ing inactive cortisone. Glucocorticoids (mineralocorti-
coids as well) increase vascular tone by potentiating the
vasoconstrictor action of Ang II and a-adrenergic cate-
cholamines. An increase in available glucocorticoids
could make vascular cells more responsive to circulatory
vasoconstricting hormones. Thus, local glucocorticoids
metabolism played by 11bHSD1 within vascular wall
may be important in the control of vascular tone. Fur-
thermore, we demonstrated that diminished vascular
11bHSD2 activity enhances the effect of cortisol partly
by the activation of MR. However, because we adminis-
tered high concentrations of cortisol into HCASMCs,
saturation or direct inhibition of this enzyme by excess
Fig. 3. Effect of cortisol on angiotensin II (Ang II) binding in cortisol might lead to the existence of unmetabolizedHCASMCs. Confluent cells were incubated with cortisol in the absence
cortisol acting as a mineralocorticoid.(A) or presence (B) of the receptor antagonists for 24 hours, and then
Ang II binding was performed. *P , 0.01 compared with control; **P , To clarify the potential and pathophysiological role of
0.05; ***P , 0.01 compared with cells cultured with 1 mmol/L cortisol 11b-HSD2, we manipulated 11b-HSD2 gene expressionalone. (Reprinted with permission from Lippincott Williams & Wilkins,
with an antisense oligonucleotide. Although licorice andHypertension [9].)
carbenoxolone have been shown to be potent inhibitors
of 11bHSD [16], we did not attempt to administer these
agents into HCASMCs because of the nonspecific inhibi-
incubated with 0.5 mmol/L cortisol for 24 hours. The AS tion of both dehydrogenase and oxoreductase reactions.
induced dose-dependent increases in Ang II binding, The dehydrogenase activity of HCASMCs was decreased
with a maximal increase (48 6 5%) at 10 mmol/L AS by nearly 80%, but oxoreductase activity was unaffected.
(Fig. 4A). The NS did not alter the Ang II bindings. We Brem et al reported that only the oxoreductase activity
then investigated whether the up-regulation was medi- was affected with 11bHSD1 antisense oligonucleotides
ated through GR or MR. HCASMCs were exposed to in rat aortic endothelial cells [17]. These observations
RU38486 or spironolactone and then assayed for Ang raise the possibility that the dehydrogenation is mediated
II binding under the presence of 0.5 mmol/L cortisol in vivo by 11bHSD2 alone.
and 10 mmol/L AS (Fig. 4B). The up-regulated Ang II Mineralocorticoid target tissues such as the kidney
binding in the cells was significantly inhibited by the contain 11bHSD activity. In congenital or acquired
11bHSD-deficient states, suppression of 11bHSD2 activ-presence of spironolactone or RU38486. The effects of
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Fig. 4. Effect of antisense oligonucleotides
on Ang II binding in HCASMCs. After con-
fluent cells had been incubated with the oligo-
nucleotides, the cells were further incubated
with 0.5 mmol/L cortisol in the absence (A) or
presence (B) of the receptor antagonists for 24
hours, and then Ang II binding was performed.
*P , 0.05; **P , 0.01 compared with control;
†P , 0.05; ††P , 0.01 compared with cells
cultured with 10 mmol/L AS and 0.5 mmol/L
cortisol in the absence of the receptor antago-
nists. (Reprinted with permission from Lip-
pincott Williams & Wilkins, Hypertension [9].)
ity in the kidney has been believed to cause renal miner- sure may be independent of renal mineralocorticoid ex-
cess. In the administration of glucocorticoids to rats,alocorticoid excess, resulting in sodium retention and
hypertension. However, after the administration of increased vascular responses to pressor hormones pre-
cede the rise in blood pressure, which is not associated11bHSD inhibitors, there was a discrepancy between
sodium retention (which occurs in the first few days) and with renal MR [19, 20]. The present study has shown that
11bHSD could modulate the access of glucocorticoidselevated blood pressure (which occurs only after chronic
administration) [18]. Therefore, the rise in blood pres- to vascular receptors and influence vascular tone. We
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CH, Edwards CR: Mineralocorticoid activity of liquorice: 11Beta-propose that vascular 11bHSD2 activity could influence
hydroxysteroid dehydrogenase deficiency comes of age. Lancet
blood pressure by this mechanism without invoking renal 2:821–824, 1987
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Human hypertension caused by mutations in the kidney isozyme
of 11beta-hydroxysteroid dehydrogenase. Nat Genet 10:394–399,
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